CXCL10-FTH-MSC

CXCL10-FTH-MSC is an engineered cell therapy consisting of mesenchymal stem cells (MSCs) transduced with a recombinant lentivirus to overexpress the chemokine CXCL10, the anti-apoptotic transcription factor Nrf2, and a ferritin heavy chain (FTH) reporter gene. Developed for the treatment of glioblastoma (GBM), this therapeutic approach utilizes MSCs as a delivery vehicle to the tumor microenvironment. CXCL10 is intended to recruit and activate T lymphocytes, converting "cold" tumors into "hot" ones, while Nrf2 enhances the survival and oxidative stress tolerance of the MSCs within the hostile tumor environment. The inclusion of the FTH gene allows for non-invasive monitoring of the cells' distribution and persistence using MRI. Preclinical data indicates that peritumoral administration of these cells, particularly when combined with immune checkpoint blockade, can significantly inhibit tumor growth and improve survival by remodeling the immune landscape of the tumor.

Other names

CXCL10 and Nrf2-overexpressed MSCsCXCL-10 and Nrf2-overexpressed MSCsCXCL 10 and Nrf2-overexpressed MSCsCXCL10-Nrf2-FTH-MSCsCXCL-10-Nrf2-FTH-MSCsCXCL 10-Nrf2-FTH-MSCs